RAF265

• Description :

  RAF265 is a potent and orally active RAF/VEGFR2 inhibitor.

• Product Name Alternative :

  CHIR-265

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Apoptosis; Autophagy; Raf; VEGFR

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Autophagy; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/RAF265.html

• Purity :

  99.80

• Solubility :

  DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C) |Ethanol : 10 mg/mL (ultrasonic)

• Smiles :

  FC(F)(C1=CN=C(N1)C2=NC=CC(OC3=CC=C4N(C(NC5=CC=C(C(F)(F)F)C=C5)=NC4=C3)C)=C2)F

• Molecular Formula :

  C24H16F6N6O

• Molecular Weight :

  518.41

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Mordant P, et al. Dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, and RAD001 (Everolimus) in combination. Mol Cancer Ther. 2010 Feb;9 (2) :358-68.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• Isoform :

  Raf; VEGFR2/KDR/Flk-1

• CAS Number :

  [927880-90-8]